

Lichen planus verrucosus in an association with vitiligo

Lichen planus verrucosus in Zusammenhang mit Vitiligo

Authors

R. Petrosian¹, K. Liesionyte¹, A. Petkevicius¹, V. Kucinskiene¹, J. Makstiene², S. Valiukeviciene¹

Institutions

¹ Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania
² Department of Pathology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania

Bibliography

DOI <http://dx.doi.org/10.1055/s-0034-1392808>
 Published online: 13.8.2015
 Akt Dermatol 2015; 41: 425–427
 © Georg Thieme Verlag KG
 Stuttgart · New York
 ISSN 0340-2541

Corresponding author

Prof. Skaidra Valiukeviciene
 Leiterin der Klinik für
 Dermatologie und Venerologie
 Litauische Universität für
 Gesundheitswesen
 Eiveniu 2
 50009 Kaunas
 Litauen
 Skaidra.valiukeviciene
 @kaunoklinikos.lt

Abstract

Lichen planus (LP) is a chronic inflammatory disease with characteristic skin lesions and histological findings. Hypertrophic lichen planus, also known as lichen planus verrucosus, is a subtype of lichen planus. Lichen planus verrucosus is clinically characterized by pruritic symmetric hyperkeratotic plaques of red, yellow-gray, red-brown or purplish-grey colour, usually located

on the pretibial or perimalleolar areas, less often on the arms or trunk. Lichen planus affects about 0.5–1% of the population. Hypertrophic lichen planus is a less common form of lichen planus. It accounts for 4.7% of lichen planus cases. The disease has a chronic course, and it is often resistant to local and systemic treatment. This article describes a rare lichen planus verrucosus form in association with vitiligo.

Case Report

A 72-year-old woman presented with itchy rash on various parts of the body. The first lesions appeared on the extensor surfaces of the arms four years ago and had now spread to the neck and legs with intensive itching. Medical history included vitiligo beginning at the age of 27, as well as arterial hypertension which was diagnosed 15 years ago and for which she had been treated with Nebivolol 5 mg once daily continuously. Clinical examination revealed round, pink 0.5–1.5 cm nodules with hyperkeratotic surface on the pretibial surfaces, the back, extensor surfaces of the arms and on the neck (● Fig. 1 a–d) as well as symmetrical vitiligo lesions. Her fingernails and toenails showed yellow discolouration, splitting and were hyperkeratotic (● Fig. 1 a, c). Milky white reticular papules were seen on the oral mucosa. Patch testing with baseline series of European allergens and topical corticosteroids was negative. Laboratory findings showed iron-deficiency anaemia. C-reactive protein, liver enzymes, creatinine, urea and urine analysis were normal. Further investigations including chest X-ray, sonography of abdomen, peripheral lymph nodes and thyroid gland showed no pathological changes. Gastrointestinal endoscopy identified erosive gastritis. Dermatohistological examination of a lesion from the neck area showed hyperkeratosis, hypergranulosis, papillomatosis, acanthosis, band-like lym-

phocyte infiltration with eosinophils, the presence of civatte and colloid bodies (● Fig. 2 a–b). These findings confirmed the diagnosis of lichen planus. The patient refused treatment with oral corticosteroids hence symptomatic treatment with oral antihistamines (1st and 2nd generation), topical high potency steroids and UVA phototherapy was commenced. Additionally the patient was recommended to change the antihypertensive medication, which may have been associated with her skin condition.

Discussion

Lichen planus (LP) was first described by Erasmus Wilson in 1869 [1]. The dermatosis (LP) is a chronic inflammatory disease of unknown etiology characterized by pink to purple colour, flat-topped, pruritic polygonal papules on the skin or milky white reticular papules on the oral mucosa [2]. Hypertrophic LP, also known as lichen planus verrucosus, is a chronic form of LP [3]. LP affects about 0.5–1% of the population [4,5]. Hypertrophic LP constitutes 4.7% of lichen planus cases and 2.2% of all lichenoid tissue reactions [6]. LP verrucosus is clinically characterized by pruritic symmetric hard and hyperkeratotic plaques of red, yellow-grey, red-brown or purplish-grey colour, usually located on the pretibial or perimalleolar areas, less often on the arms or trunk [4, 7–



Fig. 1 Pruritic symmetric hard and hyperkeratotic nodules of red, red-brown or purplish-grey colour more prominent on the frontal shins with vitiligo symmetrically area (a–c) and less prominent on the back (d).

11]. LP verrucosus diagnosis is based on the clinical and histopathological findings of the lesions. The histopathological findings of LP reveal orthohyperkeratosis, circumscribed wedge-shaped hypergranulosis, acanthosis and – in case of hyperkeratotic form of LP – hyperkeratosis of epidermis. In the upper dermis a band-like lymphocytic infiltrate is observed and vacuolar degeneration with apoptotic keratinocytes (colloid bodies) at the dermoepidermal junction area [12–14]. Hypertrophic LP may resemble chronic lichen simplex, prurigo nodularis, lichenoid cutaneous amyloidosis, Kaposi's sarcoma, stasis dermatitis and psoriasis [15]. Alomari et al. suggest that some cases (20.6%) of hypertrophic LP show prominent numbers of eosinophils. Therefore hypertrophic LP should be considered in the differential diagnosis of lichenoid drug eruption [16]. Medications that can cause lichenoid drug eruptions include beta-blockers (latency period, 1 year), penicillamine, antimalarial agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs, benzothiadiazides and




Fig. 2 Histopathologic findings: acanthosis, hyperkeratosis, band like lymphocyte infiltration in H+E staining (a), Civatte bodies and colloid bodies in PAS staining (b).

more [17–19]. Typical histopathological findings of lichenoid drug eruption are focal parakeratosis, presence of eosinophils and plasma cells, and a deeper perivascular and periadnexal infiltrate [20]. The principal differential diagnosis in this case was prurigo nodularis, that affects extensor surfaces of the limbs and presents as pruritic nodules, and is histologically characterised by hyperkeratosis, parakeratosis, irregular acanthosis, the inflammatory infiltrate in the dermis with lymphocytes, mast cells, histiocytes and occasionally eosinophils [21]. In our case hyperkeratotic LP was associated with vitiligo. S. Baghestani et al. have reported familial coexistence of LP and vitiligo, correspondingly, J. Wyte et al. – a case of long-standing vitiligo that was spared in LP [22, 23]. G. Kravvas et al. reviewed many theories of LP association with vitiligo as sun-exposed depigmented areas play an important part in the initiation of LP; the evident manifestation of the Koebner phenomenon in vitiligo area. Another theory is that long-standing vitiligo alters the expression of antigens identified by effector T cells in LP, thus leading to the pathophenotype of LP [24–30]. Longstanding, non-healing, severely itching hypertrophic LP lesions are prone to develop malignancy. There are reports of metastatic squamous cell carcinoma and keratoacanthoma arising from long standing hypertrophic lesions [31, 32]. A.R. Bowen et al. study reports, that distinguishing keratoacanthoma and hypertrophic LP can be difficult because both have similar histopathological features, and evaluation of p53, MIB-1

and perforating elastic fibers is a tool in differential diagnosis [33]. The first-line treatment of hypertrophic LP is corticosteroids which can be applied topically or given systemically, topical calcineurin inhibitors, phototherapy, systemic retinoids, notably acitretin, systemic cyclosporine, thalidomide and mycophenolate mofetil [2, 34]. Itch is also an obsessive and burdensome symptom of hypertrophic LP. According to K. Welz-Kubiak and A. Reich pathogenesis of itch in LP is still not fully understood, so there are no effective therapeutic modalities alleviating pruritus [35]. Sometimes oral antihistamines may be used to control pruritus [34]. In this case lesions were resistant to topical treatment, especially hypertrophic LP lesions with symmetrical vitiligo areas. Our case doesn't rule out the possibility that hypertrophic LP could be partially induced by antihypertensive drugs. The treatment of LP should be given for a long time and patient follow-up is vital in order to detect malignant transformation of the lesions.

Conflict of Interest

The authors declare no conflict of interest.

Zusammenfassung

Lichen planus verrucosus in Zusammenhang mit Vitiligo

Lichen planus (LP) ist eine chronische Hautkrankheit, die klinisch typische Hautveränderungen aufweist und durch eine typische Histologie gekennzeichnet ist. Der hypertrophe LP, auch als Lichen planus verrucosus bekannt, zeichnet sich durch juckende, symmetrische, hyperkeratorische, gelbgraue, rotbraune oder rötlichgraue Papeln aus, meist an der Vorderseite der Unterschenkel oder in der Knöchelregion, seltener an Händen oder am Rumpf. Die Häufigkeit des LP liegt bei 0,5–1%. Der hypertrophe LP ist eine seltene Form, die nur bei 4,7% der Lichen planus-Fällen gefunden wird. Diese Krankheit verläuft chronisch und ist üblicherweise recht therapieresistent gegenüber topischer und systemischer Behandlung. Dieser Beitrag beschreibt die seltene Form des Lichen planus verrucosus in einer Assoziation mit Vitiligo.

References

- Kanwar AJ, De D. Lichen planus in children. *Indian J Dermatol Venereol Leprol* 2010; 76: 366–372
- Jerez Jaime T, Jerez Jaime T, Mello Guaraldi B et al. Disseminated hypertrophic lichen planus: relevant response to acitretin. *An Bras Dermatol* 2011; 86: 96–99
- Paravina M. Hypertrophic Lichen Planus – a Case Report. *Serbian Journal of Dermatology and Venereology* 2014; 6: 73–80
- Pinter A, Patzold S, Kaufmann R. Lichen planus of nails – successful treatment with Alitretinoin. *J Dtsch Dermatol Ges* 2011; 9: 1033–1034
- Staubach P. Lichen planus. *CME Dermatol* 2009; 4: 68–79
- Kumar UM, Yelikar BR, Inamadhar AG et al. A clinico-pathological study of lichenoid tissue reactions – a tertiary care experience. *J Clin Diagn Res* 2013; 7: 312–316
- Karadaglic D, Pavlovic M. Lichen planus i lichenoidne reakcije. *Dermatologija*. Beograd: Vojnoizdavački zavod; 2000: 973–984
- Jaime TJ, Guaraldi BM, Melo DF et al. Disseminated hypertrophic lichen planus: relevant response to acitretin. *An Bras Dermatol* 2011; 86: 96–99
- Hornstein OP, Holländer K, Simon JR et al. Klinische Feldstudie zur Häufigkeit und topographischen Verteilung des Lichen ruber einschließlich der Frage ätiologischer Einflussfaktoren. *Z Hautkr* 1980; 55: 1562–1568
- Bonnekoh B, Kuhn A. Plattenepithelkarzinom auf Lichen ruber hypertrophicus – Fallbericht mit Literaturübersicht. *Z Hautkr* 1986; 61: 394–402
- Sigurgeirsson B, Lindelöf B. Lichen planus and malignancy. *Arch Dermatol* 1991; 127: 1684–1688
- Caspary J. Über Lichen ruber. *Vierteljahresschrift f. Dermatol u. Syph* 1888; 20: 158–163
- King DF. The Caspary Robinson Space. *Am J Dermatopathol* 1984; 6: 161–162
- Wagner G, Rose C, Sachse MM. Clinical variants of lichen planus. *JDDG* 2013; 11: 309–319
- Gorouhi F, Davari P, Fazel N. Cutaneous and Mucosal Lichen Planus: A Comprehensive Review of Clinical Subtypes, Risk Factors, Diagnosis and Prognosis. *The Scientific World Journal* 2014; 2014: 1–22
- Alomari A, McNiff JM. The significance of eosinophils in hypertrophic lichen planus. *Journal of Cutaneous Pathology* 2014; 41: 347–352
- Halevy S, Shai A. Lichenoid drug eruptions. *J Am Acad Dermatol* 1993; 29: 249–255
- Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. *Australas J Dermatol* 2006; 47: 57–59
- Ruiz Villaverde R, Blasco Melguizo J, Linares Solano J et al. Lichen planus-like eruption due to enalapril. *J Eur Acad Dermatol Venereol* 2003; 17: 612–614
- Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruptions and idiopathic lichen planus: retrospective study on selected samples. *Dermatologica* 1989; 179: 10
- Lee RM, Shumac S. Prurigo nodularis: A review. *Australasian Journal of Dermatology* 2015; 46: 211–220
- Baghestani S, Moosavi A, Eftekhari T. Familial Colocalization of Lichen Planus and Vitiligo on Sun Exposed Areas. *Ann Dermatol* 2013; 25: 223–225
- Wyte J, Wilkinson JD. Unilateral lichen planus, sparing vitiliginous skin. *Br J Dermatol* 1995; 133: 817–818
- Kravvas G, Veitch D, Bunker C. A rare case of colocalization between lichen planus and vitiligo. *Department of Dermatology, University College London Hospitals*
- Ujije H, Sawamura D, Shimizu H. Developent of lichen planus and psoriasis on lesions of vitiligo vulgaris. *ClinExpDermatol* 2006; 57: 690–699
- Sardana K, Sharma RC, Koranne RV et al. An interesting case of colocalization of segmental lichen planus and vitiligo in a 14-year-old boy. *Int J Dermatol* 2002; 41: 508–509
- Göktay F, Mansur AT, Aydingoz IE. Colocalization of vitiligo and lichen planus on scrotal skin: a finding contrary to the actinic damage theory. *Dermatology* 2006; 212: 390–392
- Rubisz-Brzezinska J, Büchner SA, Itin P. Vitiligo associated with lichen planus. Is there a pathogenetic relationship? *Dermatology* 1996; 192: 176–178
- Bagestani S, Moosavi A, Eftekhari T. Familial colocalization of lichen planus and vitiligo on sun exposed areas. *Ann Dermatol* 2013; 25: 223–225
- Anstey A, Marks R. Colocalization of lichen planus and vitiligo. *Br J Dermatol* 1993; 128: 103–104
- Audhya M, Varughese JS, Nakhwa YC. Verrucous lichen planus: a rare presentation of a common condition. *Dermatology Reports* 2014; 6: 10–11
- Friedl TK, Flaig MJ, Ruzicka T et al. Verrucous squamous cell carcinoma complicating hypertrophic lichen planus. Three case reports and review of the literature. *Hautarzt* 2011; 62: 40–45
- Bowen AR, Burt L, Boucher K et al. Use of proliferation rate, p53 staining and perforating elastic fibers in distinguishing keratoacanthoma from hypertrophic lichen planus: a pilot study. *Journal of Cutaneous Pathology* 2012; 39: 243–250
- Usatine PR, Tanitigan M. Diagnosis and Treatment of Lichen Planus. *Americal Family Physician* 2011; 53–60
- Welz-Kubiak K, Reich A. Mediators of Pruritus in Lichen Planus. *Auto-immune Diseases* 2013; 2013: 1–4